The project management is responsible for the content of the information provided.
This project is one of the seven winners of the «Microbials - Direct Use of Micro-Organisms», call 2019. Project partners: Food Biotechnology Laboratory - ETH Zürich; Gastroenterology and Nutrition Unit of the Children’s Hospital Zürich (KISPI).
Förderbeitrag: CHF 300'000
Dauer: 02.2020 - 08.2022
Handlungsfeld: Microbials, seit 2016
PhD Vanesa Natalin Rocha Martin
Laboratory of Food Biotechnology
8092 Zürich (Schweiz)
- vanesa.rocha@hest. ethz. ch
Infant Colic (IC) affects up to 20% of infants younger than three months. Colicky babies experience prolonged and inconsolable crying, which affect the infants and parents' life, and are frequent trigger for abusive head trauma: “Shaken Baby Syndrome”. IC is defined as sudden fussing or crying lasting more than three hours per day and occurring at least three days each week and for at least one week. There is currently no treatment with proven efficacy on IC.
Our studies involving infant cohorts, animal and in vitro models, provide scientific evidence on the role of the gut microbiota metabolism as cause of IC. Our work revealed that excessive hydrogen (H2) production by lactate-utilizing bacteria inhabiting the infant gut, is likely the cause for flatulence and bloating and associated pain in IC.
Our goal is to develop the first mechanistic-based live microbial product for prevention and treatment of IC applying a selected and demonstrated Propionibacterium spp. strain, metabolizing lactate in infant gut conditions without the production of H2. The current project will allow the translation of our scientific discoveries into a treatment that will improve infant health and family well-being.
Was ist das Besondere an diesem Projekt?
This project is based on a strong scientific background and data built on more than 12 years of research on IC by the Food Biotechnology Laboratory - ETH Zürich and in collaboration with the Gastroenterology and Nutrition Unit - KISPI. The proposed project has a unique mechanistic basis for the approach and will result in the identification of high potential strain of Propionibacterium for the effective microbial-based treatment of IC. It will provide the required data for conducting preclinical studies and developing a clinical study protocol in infants involving 3-4 clinical centers in different EU countries to demonstrate efficacy of the final strain in the treatment of IC.
The project started on 1 February 2020
Chassard, C., Lacroix, C., Braegger. (2014). Baby Food Composition comprising viable propionic acid-producing bacteria. International Patent. WO2014/110685;
Pham, V.T., Lacroix, C., Braegger, C.P., Chassard, C. (2017) Lactate-utilizing com- munity is associated with gut microbiota dysbiosis in colicky infants. Sci Rep 7, 11176;
Rocha Martin, V.N., Schwab, C., Krych, L., Voney, E., Geirnaert, A., Braegger, C., Lacroix, C. (2019) Colonization of Cutibacterium avidum during infant gut microbiota establishment. FEMS Microbiol Ecol 95, fiy215.
No media echo yet
Am Projekt beteiligte Personen
Letzte Aktualisierung dieser Projektdarstellung 10.02.2020